Core Insights - The recent academic conferences in Yixing and Chengdu highlighted the innovative radar magnetic technology for pelvic health, showcasing its clinical applications and research advancements [1][2][3] Group 1: Clinical Applications - The radar magnetic technology is being recognized for its potential in addressing male pelvic floor disorders, particularly chronic pelvic pain syndrome (CP/CPPS), with a multi-center clinical research project officially launched [2] - For female pelvic health, the technology is being integrated into a comprehensive management system that combines various treatment modalities, demonstrating significant clinical advantages in treating conditions like post-prostatectomy urinary incontinence [3][5] Group 2: Technological Innovation - The radar magnetic technology utilizes a combination of millimeter-wave radar and magnetic stimulation for non-invasive monitoring of pelvic muscle contraction states, offering personalized treatment options for patients with varying muscle strength [3] - The integration of virtual and augmented reality technologies with radar magnetic assessments is expected to enhance patient compliance and remote healthcare capabilities [4] Group 3: Market Potential - The demand for pelvic health solutions is rapidly increasing due to aging populations and heightened health management awareness, positioning radar magnetic technology as a key player in the billion-dollar pelvic health market [6][7] - The technology's unique advantages in non-invasive assessment and intelligent treatment strategies are set to redefine diagnostic and therapeutic standards in pelvic health [6][7]

| 回购方案首次披露日 | 2024/7/2，由控股股东杨瑞嘉先生和史志怀先生提议 | | | --- | --- | --- | | 回购方案实施期限 | 年 月 年 月 2024 7 1 日~2025 6 30 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | 回购价格上限 | 31.61元/股 | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 □为维护公司价值及股东权益 | | | 实际回购股数 | 108.21万股 | | | 实际回购股数占总股本比例 | 1.08% | | | 实际回购金额 | 2,135.1187万元 | | | 实际回购价格区间 | 18.57元/股~26.00元/股 | | 一、回购审批情况和回购方案内容 2024 年 6 月 24 日，南京麦澜德医疗科技股份有限公司（以下简称"公司"）控 股股东杨瑞嘉先生和史志怀先生向公司董事会提议公司以自有资金通过集中竞价 交易方式实施股份回购。2024 年 7 月 1 日，公司召开第二届董事会第八次会议， 审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》， ...

Core Viewpoint - The company is focusing on expanding its business in the urology sector, particularly in the treatment of prostate diseases, which is expected to become a new growth point in the next 2-3 years [1][3]. Group 1: Business Performance - As of May 23, 2025, the company's stock price closed at 28.7 yuan, up 1.16% from the previous week, with a total market capitalization of 2.87 billion yuan [1]. - The company ranks 101 out of 126 in the medical device sector and 4226 out of 5148 in the A-share market [1]. Group 2: Product and Market Strategy - The decline in gross margin for the pelvic floor business is attributed to the initial low margins of new product promotions, but margins are expected to gradually recover as system solutions and combination sales strategies are implemented [1][3]. - The company is focusing on non-invasive brain-computer interface technology for neurodegenerative diseases, targeting conditions such as Alzheimer's and Parkinson's, with plans to expand application scenarios [1][3]. Group 3: Overseas Expansion - The short-term goal for overseas business is to deepen penetration in the Asia-Pacific market, while the long-term strategy shifts from "product output" to "demand-driven" approaches [2][3]. - The promotion of the Kangmei Center is still in its early stages, facing challenges such as medical insurance reimbursement limitations, while establishing model centers in Jiangsu and Zhejiang [2][3]. Group 4: Sales Strategy - The company employs a unique sales strategy that combines serious medical consumption with consumer medical seriousness, utilizing a tiered distribution model in serious medical markets and a multi-faceted marketing approach in consumer medical markets [2][3].

Group 1: Yuntu Holdings - Yuntu Holdings introduced its integrated development strategy for nitrogen and phosphate fertilizer supply chains, aiming for stable growth in compound fertilizer sales during the spring farming season in Q1 2025 [1] - The company has nearly 6,000 first-level distributors and is enhancing channel construction and marketing integration [1] - The production of various phosphate compound fertilizer products through graded utilization of phosphoric acid is expected to become a new profit point, with a 700,000-ton synthetic ammonia project enhancing the nitrogen fertilizer supply chain and adding 1 million tons of compound fertilizer capacity [1] Group 2: Mcland - Mcland is collaborating with benchmark hospitals in the urology market, anticipating that the male prostate disease market will become a new growth point in the next 2-3 years [2] - The gross margin of the pelvic floor business has declined due to low margins in the initial phase of new product promotion, but margins are expected to gradually recover [2] - The company is focusing on non-invasive brain-computer interface technology for neurodegenerative diseases and plans to expand application scenarios, with nearly half of its R&D investment directed towards AI-related projects [2] Group 3: Lier Chemical - Lier Chemical expects a recovery in Q1 2025, with some product sales and prices increasing year-on-year, and cost reduction and efficiency improvement measures yielding results [3] - The pesticide industry supply-demand situation is improving, although competition remains fierce, with growing demand for glyphosate but prices at low levels [3] - The company is optimistic about the market prospects for refined glyphosate, with ongoing discussions regarding an incentive plan and due diligence on the acquisition of Shandong Huimeng [3]

Group 1 - The core viewpoint of the article highlights that 麦澜德 is focusing on the male prostate disease market, which is expected to become a new growth point in the next 2-3 years [1] - 麦澜德's gross margin in the pelvic floor business has declined due to low margins from new product promotions, but it is anticipated to gradually recover and stabilize [1] - The company is concentrating on common scenarios such as stroke and neurological injury rehabilitation, with its pricing policy still in the improvement phase [1] Group 2 - 麦澜德 employs non-invasive brain-machine interface technology, targeting neurodegenerative diseases, strokes, and pediatric cerebral palsy, with plans to expand application scenarios in the future [1] - The short-term goal for overseas business is to deepen the Asia-Pacific market, while the medium to long-term goal shifts from "product output" to "demand-driven" [1] - Nearly half of the research and development investment is allocated to projects involving AI technology [1] Group 3 - The promotion of 康美中心 is still in its early stages, facing core challenges such as medical insurance pricing restrictions, insufficient market pricing mechanisms in hospitals, and consumer demand recognition [1] - The company adopts a tiered distribution model in the serious medical market and a multi-faceted marketing approach in the consumer medical market, emphasizing compliant promotion [1]

投资者可于 2025 年 5 月 19 日(星期一)至 5 月 23 日(星期五)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 24 日发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2024 年度及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 26 日上午 09:00-10:00 举行 2024 年度暨 2025 年第一季度业绩暨现 金分红说明会，就投资者关心的问题进行交流。 证券代码：688273 证券简称：麦澜德 公告编号：2025-018 南京麦澜德医疗科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-017 南京麦澜德医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 05 月 14 日 （二） 股东大会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 54 | | --- | --- | | 普通股股东人数 | 54 | | 2、出席会议的股东所持有的表决权数量 | 65,460,122 | | 普通股股东所持有表决权数量 | 65,460,122 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 66.9272 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.9272 | （四） ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024 年度持续督导跟踪报告 2022 年 8 月 11 日，南京麦澜德医疗科技股份有限公司（以下简称"麦澜德" 或"公司"）在上海证券交易所科创板上市。根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》等相关规定，南京证券股份有限 公司（以下简称"南京证券"或"保荐机构"）作为麦澜德的保荐机构，对麦澜 德进行持续督导，持续督导期为 2022 年 8 月 11 日至 2025 年 12 月 31 日。 2024 年度，南京证券对麦澜德的持续督导工作情况如下： | 序号 | 工作内容 | 持续督导情况 | 保荐机构已建立并有效执行了持 | | | | --- | --- | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针对 | 续督导制度，并制定了相应的工 | 1 | 具体的持续督导工作制定相应的工作计划 | | | | 作计划 | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与麦澜德签订保荐协 | | | | | 前，与上市公司或相关当事人签署持续督导协 | 议，该协 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of 麦澜德 in the medical device industry, showcasing its recent achievements and financial metrics [1][2] - 麦澜德's stock closed at 29.62 yuan, with a rolling PE ratio of 28.17, marking a new low in 32 days, and a total market capitalization of 29.62 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE ratio of 49.20 and a median of 36.56 [1][2] Group 2 - For Q1 2025, 麦澜德 reported revenue of 1.18 billion yuan, reflecting a year-on-year increase of 13.36%, and a net profit of 3985.97 million yuan, up by 9.85%, with a gross margin of 70.85% [2] - The company specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on women's health [1] - 麦澜德 has been recognized as a "national manufacturing single champion" and is the first national-level specialized and innovative "little giant" enterprise in its field, indicating strong market competitiveness and innovation capabilities [1]